Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 22 January 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Long-term lamivudine therapy for children with Hep B

The latest Hepatology issue reports further clinical response in Hep B e antigen-positive children who did not achieve a virological response after 1 year of lamivudine.

News image

fiogf49gjkf04

A year of lamivudine treatment results in increased Hepatitis B e antigen seroconversion

It also leads to serum Hepatitis B virus DNA negativity in children with chronic Hepatitis B and high serum alanine aminotransferase concentrations.

Dr Etienne Sokal and colleagues from Belgium conducted a 1-year randomized, placebo-controlled study of lamivudine in 276 children.

The patients were stratified into 2 groups based on Hepatitis B e antigen status at week 48 of the previous study.

The investigative team entered 213 Hepatitis B e antigen-positive children into a treatment arm.

A further 63 Hepatitis B e antigen-negative children were entered into an observation arm to evaluate durability of Hepatitis B e antigen loss.

The team's primary endpoint included virological response, or Hepatitis B e antigen loss and Hepatitis B virus DNA negativity, at month 24.

In the treatment arm, 21 % of children previously treated with lamivudine achieved the primary endpoint.

21% previously treated achieved virological response vs 30% with placebo
Hepatology

Of the children who previously received placebo, 30% achieved virological response.

The investigators assessed the incidence of YMDD - tyrosine, methionine, aspartate, aspartate - mutations at month 24.

In the children previously treated with lamivudine, the incidence of YMDD mutations at month 24 was 64% vs 49% in those treated with placebo.

The incidence of virological response at month 24 was 5% for patients with YMDD mutant Hepatitis B virus and 54% for patients without.

In addition, the investigators found that the durability of response in the observation arm was 89% at month 24.

Dr Sokal's team concluded, “Further clinical response was seen over the 24-month open-label study period in children who had not initially achieved a virological response after 12 months of lamivudine treatment.”

“However, the incidence of YMMD mutations increased over time and resulted in lower response rates.”

“Virological response was maintained in most patients who had initially responded to lamivudine in the first 12 months.”

Hepatol 2006: 43(2): 225-32
30 January 2006

Go to top of page Email this page Email this page to a colleague

 22 January 2018 
Costs of biologic therapies for IBD in the USA
 22 January 2018 
Western vs Asian guidelines for colon cancer management
 22 January 2018 
Improving symptoms in GERD
 19 January 2018 
Ileoanal pouch microbiota
 19 January 2018 
Predicting the risk of early surgery in Crohn’s
 19 January 2018 
Lifestyle intervention vs gastric bypass for obesity and diabetes
 18 January 2018 
Healthcare costs of liver cancer in the USA
 18 January 2018 
High-risk adenomas at colonoscopy
 18 January 2018 
Sleeve gastrectomy vs Roux-en-Y gastric bypass
 17 January 2018 
“Weekend effect” in upper GI hemorrhage
 17 January 2018 
Gut dysbiosis and non-antibiotic prescription medications
 17 January 2018 
Reducing surgical infections in high-outlier colorectal unit
 16 January 2018 
Bundle of care in GI cancer surgery
 16 January 2018 
Anxiety about colonoscopy
 16 January 2018 
Thiopurines and colorectal neoplasia in IBD
 15 January 2018 
Risks of death after liver transplants for liver cancer
 15 January 2018 
Recent advances in hepatocellular carcinoma
 15 January 2018 
Ileostomy output using telemedicine
 12 January 2018 
Surveillance protocols after colorectal cancer resection
 12 January 2018 
Biologic therapy by pregnant women with IBD and infant vaccines
 12 January 2018 
Biologic therapies for IBD in the USA
 11 January 2018 
Genetic risk factors in GERD
 11 January 2018 
Predictor of colorectal adenoma
 11 January 2018 
Ectopic pregnancy in IBD 
 10 January 2018 
Fecal immunochemical tests for colorectal cancer screening
 10 January 2018 
Risk factors for advanced NAFLD
 10 January 2018 
Dyspepsia prevalence with gastroesophageal reflux–type symptoms
 09 January 2018 
Screening intervals for people with family histories of colorectal cancer
 09 January 2018 
Financial impact of colorectal cancer
 09 January 2018 
Current practice and future research in autoimmune hepatitis
 08 January 2018 
Reliability of the IBD index
 08 January 2018 
Improving prognosis in patients with primary sclerosing cholangitis
 08 January 2018 
Aprepitant and nausea with gastroparesis
 05 January 2018 
Autoimmune pancreatitis and IBD
 05 January 2018 
Primary nonresponse to infliximab therapy
 05 January 2018 
Anesthesia assistance in outpatient colonoscopy
 04 January 2018 
Dietary polyphenols in the etiology of IBD
 04 January 2018 
Local esophageal food allergen injections in eosinophilic esophagitis
 04 January 2018 
Yoga vs low-FODMAP in IBS
 03 January 2018 
Population health management for IBD
 03 January 2018 
GERD in asthma and COPD
 03 January 2018 
Critical research gaps in colorectal cancer
 22 December 2017 
Costs of extrahepatic manifestations of Hep C
 22 December 2017 
Cholera vaccine and risk of death in colorectal cancer
 22 December 2017 
Colonoscopy after colorectal cancer resection
 21 December 2017 
Human oral microbiome and pancreatic cancer risk
 21 December 2017 
Health management for IBD
 21 December 2017 
PPI and Alzheimer's disease
 20 December 2017 
Management of abnormal liver blood tests
 20 December 2017 
Incidence of biopsy-verified celiac disease
 20 December 2017 
Osteoporotic fractures in Barrett's esophagus
 19 December 2017 
Alcohol abstinence and alcoholic hepatitis
 19 December 2017 
Family burden of pediatric Crohn's in the USA
 19 December 2017 
Early readmission in IBD patients
 18 December 2017 
Colorectal cancer mortality with low-risk adenomas at colonoscopy
 18 December 2017 
Disease activity indices in celiac disease
 18 December 2017 
Smoking behaviour predicted the risk of surgery in Crohn's
 15 December 2017 
Molecular classification of Crohn's disease
 15 December 2017 
Medical cannabinoid legalization policy and vomiting
 15 December 2017 
Inflammatory diet pattern and colorectal cancer risk

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us